Stocks To Watch Tuesday - STKO, WAG, ISTA
This chain of nearly 60 stores nationwide, a subsidiary of Kitchen Collection (operating an additional 200+ stores nationwide), offers a one-stop source for home entertaining and gift giving, providing everything the consumer needs to organize a fun and festive celebration for any occasion. Le Gourmet Chef provides an enjoyable shopping experience with a great assortment of gourmet foods, kitchenware and home entertaining products. Six flavors of the Natural plus Energy™ product have been incorporated into the new planogram for the entire chain.
Peter Hellwig, President & CEO of Stakool and Anthus Life, states,"We are extremely excited about this opportunity to align with such a fine retailer as Le Gourmet Chef. The physical placement of our product is attractive and strategic. We expect the product to move very well through this chain, and possibly through Kitchen Collection in the future as well. This deployment is a significant development in the Company's strategy of bringing on national retailers and raising the profile of the brand."
What They Do: Stakool Inc., through its wholly-owned subsidiary, Anthus Life Corp., is committed to being a leading North American supplier of natural and organic and health and wellness products. By fulfilling the highest standards for quality, consistency, sustainability, product assortments, value-added support services and integrity in business and personal relationships, Anthus Life brings to market complementary products that are most suited to the consumer.
Additionally, the Company's expanding product lines are complemented by an endorsement agreement with seven-time Olympic medalist Shannon Miller.
Walgreen Co. (NYSE: WAG) $34.27. Today announced earnings and record sales results for the second quarter and first half of fiscal year 2012 ended Feb. 29. Net earnings for the second quarter were $683 million, a 7.7 percent decrease from $739 million in the same quarter a year ago. Net earnings per diluted share for the quarter decreased 2.5 percent to 78 cents, compared with 80 cents per diluted share in the year-ago quarter. This year’s results benefited from one extra day versus last year because of leap year. Compared with the prior year’s quarter, the mild cough/cold and flu season impacted net earnings per diluted share by 3 cents, while the effect of no longer being part of the Express Scripts, Inc. pharmacy provider network as of Jan. 1, 2012, impacted results by 7 cents per diluted share.
Net earnings per diluted share for the first half of fiscal 2012 ended Feb. 29 were $1.41 per diluted share, a decrease of 0.8 percent from $1.42 per diluted share in the first half of fiscal 2011. This year’s results include the impact of 9 cents per diluted share from the effect of no longer being part of the Express Scripts network and the impact of 1 cent per diluted share in drugstore.com operations and integration costs. Last year’s results include the impact of 1 cent per diluted share in restructuring and restructuring-related costs associated with Rewiring for Growth and 1 cent per diluted share in Duane Reade integration costs. Net earnings for the first half of fiscal 2012 were $1.24 billion versus last year’s $1.32 billion, a 6.3 percent decrease.
What They Do: Walgreens operates 8,290 locations in all 50 states, the District of Columbia, Puerto Rico and Guam. The company has 7,841 drugstores nationwide, 151 more than a year ago.
Bausch + Lomb and ISTA Pharmaceuticals (Nasdaq: ISTA) $8.38, announced Monday after market close that they have signed a definitive agreement under which Bausch + Lomb ("the Company") will acquire ISTA for $9.10 per share in cash, or a total of approximately $500 million. The transaction, which has been unanimously approved by the boards of directors of both companies, is expected to close in the second quarter of 2012.Bausch + Lomb's acquisition of ISTA accelerates the company's strategy to strengthen its pipeline and marketed products and capabilities. The transaction is expected to drive growth and high performance for the long term.
The combination adds ISTA's portfolio of industry-proven non-steroidal, anti-inflammatory, allergy, glaucoma and spreading agents to Bausch + Lomb's robust, complementary portfolio of existing Rx ophthalmology and OTC eye health products. The companies also have complementary development pipelines. ISTA's pipeline includes candidates in various stages of development to treat various ocular conditions including inflammation and pain, while Bausch + Lomb's pipeline of pharmaceutical innovations include the first of a new class of ocular anti-inflammatory agents to come along in decades, and a promising approach to reducing intra-ocular pressure in patients with open-angle glaucoma or ocular hypertension.
What They Do: ISTA Pharmaceuticals, Inc. is a fast growing and the third largest branded prescription eye care business in the United States with an expanding focus on allergy therapeutics.
SmallCapReview.com has been a leading site for information on Small Cap Stocks, Penny Stocks and Microcaps since 1999. Visit SmallCapReview.com to sign up for our FREE newsletter. SmallCapReview may hold positions in securities mentioned herein, and may make purchases or sales in such securities featured on our website or within our reports In order to be in full compliance with the Securities Act of 1933, Section 17(b), SCR will disclose in it's disclaimer, what, if any compensation was received for our efforts in researching, presenting and disseminating this information to our subscriber database and featuring the report on the SmallCapReview website. SmallCapReview has been compensated three thousand five hundred dollars by a third party Tri Star Media for its efforts with regards to Stakool.